Management of @entity1643 often includes oral opioid use. The effectiveness of therapy is dependent upon compliance, which in turn is dependent upon response, side effects, access, and convenience. Our hypothesis was that a transdermal @entity3575 system would provide more effective @entity158 management than oral opioids. Fifty @entity1 with @entity1643 were examined. After litration to levels corresponding to current oral opioid use, each @entity1 was maintained on transdermal @entity3575 for one month. Oral opioid therapy was then resumed. Their experience was assessed with the a visual analogue scale for @entity158 intensity, a numerical @entity158 score, the @entity717 questionnaire, the @entity158 disability index, and the Verran Snyder-Halpern sleep scale. Significant improvement in @entity158 was found with transdermal @entity3575 compared with oral opioids. Mild opioid side effects were common, but easily controlled. Use of transdermal @entity3575 is an effective alternative to oral opioids for managing @entity1643 .

Transdermal @entity3575 as treatment for XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity1643 :: ('MESH:D017116', 'Disease') :: ['chronic low back pain'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain relief and disability', 'pain'] @entity717 :: ('MESH:D009069', 'Disease') :: ['Oswestry disability'] @entity3575 :: ('MESH:D005283', 'Chemical') :: ['fentanyl']
@entity1643 :: (MESH:D017116,Disease) :: ['chronic low back pain']
